Company intelligence / Profile preview
Cardax, Inc.
Honolulu, Hawaii, United Statescardaxpharma.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Currently markets ZanthoSyn®, a physician-recommended astaxanthin dietary supplement. Has pre-clinical pharmaceutical candidates CDX-101 for cardiovascular inflammation and dyslipidemia, and CDX-301 for macular degeneration.
- Therapeutic areas
- GastroenterologyCardiovascularRheumatologyOphthalmologyImmunologyEndocrinologyNeurology
- Modalities
- Small moleculesdietary supplements
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
BASFCapsugel (Pfizer spin-out)
Beyond the preview
Go deeper on Cardax, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cardax, Inc..